Twenty-nine percent of contractors say a shutdown would cause them to delay planned hiring, and 58% said it would have a negative effect on their businesses, according to a survey of 925 contractors this week by the National Association of Government Contractors.
Q&A: 27 more questions answered about the shutdown
One Federal Solution, which provides information technology, health care and training services to various government agencies has furloughed 107 of its 115 employees because federal officials said they're non-essential, says CEO Abdul Baytops.
"We're concerned about employees losing faith" in the company "even though we have no control over it," Abdul says.
Best Transportation Stocks To Watch Right Now: Celsius Holdings Inc (CELH)
Celsius Holdings, Inc., incorporated on April 26, 2005, is engaged in the development, marketing, sale and distribution of functional calorie-burning beverages under the Celsius brand name. The Company focuses to combine nutritional science with mainstream beverages by using its thermogenic (calorie-burning) MetaPlus formulation. The Company does not directly manufacture its beverages, but instead outsource the manufacturing process to established third-party co-packers. The Company provides its co-packers with flavors, ingredient blends, cans and other raw materials for its beverages purchased by the Company from various suppliers. Celsius, Inc. and Elite FX, Inc. are the wholly owned subsidiaries of the Company.
The Company�� Celsius is a calorie-burning beverage. Celsius is available in seven flavors, lemon-lime, ginger ale, cola, orange and wild berry (which are carbonated) and non-carbonated green tea raspberry/acai and green tea/peach mango. Its beverages are sold in 12 ounce cans, although it has begun to market the ingredients in powdered form in individual On-The-Go packets. The Company�� customer�� include on-the-go women, age 25 to 54, who are looking for a way to burn calories and gain energy with beverages and natural alternatives to diet sodas, as well as sports enthusiasts of both sexes, who are seeking low sodium, preservative-free alternatives. During the year ended December 31, 2009, the Company developed its MetaPlus formulation into a powder that can be mixed with water.
The Company competes with The Coca-Cola Company, Dr. Pepper Snapple Group, PepsiCo, Inc., Nestl茅, Waters North America, Inc., Hansen Natural Corp., and Red Bull.
Advisors' Opinion:- [By John Udovich]
Monster Beverage Corp (NASDAQ: MNST), a mid cap marketer and distributor of energy drinks and alternative beverages, has been a monster of a performer since the end of the financial crisis as the stock is up around 308% over the past five years, but could new or overlooked players like small cap beverage stocks�Jones Soda Co (OTCMKTS: JSDA), Celsius Holdings, Inc (OTCMKTS: CELH) and Konared Corp (OTCBB: KRED) repeat that performance? A look strictly at the long term performance of all three small caps might have you thinking otherwise. After all, none of these small cap beverage stocks are profitable while�the beverage industry can be a long hard expensive slog just to increase market share by one or two points when you are competing for shelf space with industry giants like Pepsi and Coke. But past performance is just that���the past and only part of the story as there is much more to consider about these small cap beverage stocks which could also make them potential acquisition targets by larger beverage players seeking to expand their product line up with innovative products:
10 Best Information Technology Stocks To Buy Right Now: Anacor Pharmaceuticals Inc. (ANAC)
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company�s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company�s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.
Advisors' Opinion:- [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Anacor Pharmaceuticals Inc.(ANAC) swung to a profit in the fourth quarter, driven by gains from a litigation settlement and a rise in revenue. The company’s revenue beat market expectations. Shares rose 6.4% to $21.45 in light premarket trading.
10 Best Information Technology Stocks To Buy Right Now: (NWBO)
Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer in the United States. Its technology platforms comprise dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The company?s product candidates include DCVax-Prostate for the treatment of non-metastatic hormone independent prostate cancer, which cleared Phase III clinical trial; DCVax-Brain that is in Phase II clinical trial for the treatment of glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-small cell lung cancer. Its product candidates also comprise DCVax-Direct that cleared Phase I clinical trial for the treatment of ovarian, head, and neck cancer; and DCVax-L, which completed Phase I/II clinical trials for the treatment of resectable solid tumors. In addition, the company develops CXCR4 antibodies, which are involved in various phases of disease progression, including proliferation of the primary tumor, migration of cancer cells out of the primary tumor, and establishment of distant metastatic sites for the treatment of non-small cell lung cancer, breast cancer, glioblastoma multiforme, colon cancer, melanoma, prostate, pancreatic, kidney, ovarian, and certain blood cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Advisors' Opinion:- [By Smith On Stocks]
Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.
10 Best Information Technology Stocks To Buy Right Now: Broadwind Energy Inc.(BWEN)
Broadwind Energy, Inc. provides products and services to the energy, mining, and infrastructure sector customers, primarily in the United States. The company?s Towers and Weldments segment manufactures towers designed for two megawatt and larger wind turbines. This segment also manufactures specialty fabrications and weldments for mining and other industrial customers. Its Gearing segment engineers, builds, and remanufactures precision gears and gearing systems for wind, oil and gas, mining, and other industrial applications. The company?s Services segment offers a range of services, including non-routine blade and gearbox maintenance services for both kilowatt and megawatt turbines primarily to wind farm developers and operators. It also provides field services to the wind industry; dedicated drivetrain services; and industrial gearboxes precision repair and testing services. The company provides its products and services to various wind energy customers that include wi nd turbine manufacturers, wind farm developers, and wind farm operators, as well as oil and gas, mining, and other industries. It sells its products through its sales force and manufacturers' representatives. The company was formerly known as Tower Tech Holdings Inc. and changed its name to Broadwind Energy, Inc. in 2008. Broadwind Energy, Inc. is headquartered in Naperville, Illinois.
Advisors' Opinion:- [By John Udovich]
Small cap Ocean Power Technologies Inc (NASDAQ: OPTT) just sank 34% on news that they have fired their CEO "for cause,��meaning its worth taking a closer look at the stock to see if there is anything to salvage (shares were rising more than 6% in after hours) plus take a look at the performance of potential renewable energy related peers like Ormat Technologies, Inc (NYSE: ORA), Broadwind Energy Inc (NASDAQ: BWEN) and China Ming Yang Wind Power Group Ltd (NYSE: MY).
10 Best Information Technology Stocks To Buy Right Now: Peregrine Pharmaceuticals Inc.(PPHM)
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections. Its products under development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metasta tic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., provides integrated current Good Manufacturing Practices (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has licensing agreements with the University of Texas Southwestern Medical Center; Merck KGaA; SuperGen, Inc.; and Affitech A/S. Peregrine Pharmaceuticals, Inc. intends to sell its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.
Advisors' Opinion:- [By Rick Munarriz]
I went out on a limb last week, and now it's time to see how that decision played out.
I predicted that Noodles & Co. (NASDAQ: NDLS ) would close lower on the week. After seeing the fresh IPO more than double and command a $1.3 billion market cap far sooner than its fundamentals should allow, I figured it would be in for reality check. A negative Barron's piece kicked off the week in the seemingly appropriate bearish tone, but the shares did start to claw their way back later in the week. It wasn't enough. The shares fell 3% on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI ) . This has been a tricky call lately, so how did it play out this time? Well, the market closed nicely higher this week. The Nasdaq moved 3.5% higher, and the Dow managed to close just 2.2% higher. I was right. My final call was for Peregrine Pharmaceuticals (NASDAQ: PPHM ) to beat Wall Street's income estimates in its latest quarter. The upstart biotech tackling cancer through monoclonal antibodies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a loss of $0.06 a share during the quarter, and it came through with exactly that. It wasn't a beat, though, so I was wrong.Two out of three? I can do better than that.
- [By Tom Bemis]
Few major companies are reporting after Monday�� bell. Results are expected from Destiny Media Technologies (DSNY) �, Stanley Furniture Co. (STLY) � and Peregrine Pharmaceuticals. (PPHM) �.
- [By Sean Williams]
What: Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM ) , a biopharmaceutical company developing monoclonal antibodies to treat cancer, jumped as much as 19% after the company reported final data on its mid-stage second-line non-small cell lung cancer drug, Bavituximab, at the annual American Society of Clinical Oncology meeting.
10 Best Information Technology Stocks To Buy Right Now: CNH Global N.V. (CNH)
CNH Global N.V. manufactures, markets, and distributes a line of agricultural and construction equipment and parts worldwide. It operates in three segments: Agricultural Equipment, Construction Equipment, and Financial Services. The Agricultural Equipment segment provides tractors, combine harvesters, hay and forage equipment, seeding and planting equipment, tillage equipment, and sprayers, as well as cotton picker packagers, and sugar cane and grape harvesters primarily under the Case IH and New Holland brands. The Construction Equipment segment offers heavy construction equipment, such as crawler and wheeled excavators, wheel loaders, graders, dozers, and articulated haul trucks; and light construction equipment, including backhoe loaders, skid steer and tracked loaders, mini and midi excavators, compact wheel loaders, and telehandlers primarily under the Case and New Holland Construction brands. This segment serves construction companies, municipalities, local governmen ts, rental fleet owners, quarrying and aggregate mining companies, waste management companies, forestry-related concerns, contractors, residential builders, utilities, road construction companies, landscapers, logistics companies, and farmers. The Financial Services segment provides financial products and services, including retail financing for the purchase or lease of the company�s and other manufacturers� new and used products; and facilitates the sale of insurance products and other financing programs to retail customers. This segment also offers wholesale financing to its dealers and rental equipment operators, as well as financing options to dealers to finance working capital, real estate, and other fixed assets and maintenance equipment. CNH Global N.V. sells and distributes its products through dealers and distributors in approximately 170 countries. The company was founded in 1991 and is based in Amsterdam, the Netherlands. CNH Global N.V. is a subsidiary of Fiat Netherlands Holding N.V.
Advisors' Opinion:- [By vaninaegea]
In august, the Association of Equipment Manufacturers (AEM) published the mid-year review for the agricultural sector. Their findings point to a slowdown for the industry, highlighting a 9.5% decline on exports through the first half of 2013. Also, late soybean planting in the USA is expected to compound the industry�� slowdown. So, what are the prospects for AGCO (AGCO), CNH Global (CNH), and Deere & Co. (DE) under such conditions?
10 Best Information Technology Stocks To Buy Right Now: Global X China Materials ETF (CHIM)
Global X China Materials ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S-BOX China Materials Index (the Underlying Index). The Underlying Index is a free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure performance of the investable universe of companies in the Materials sector of the Chinese economy, as defined by Structured Solutions AG. Global X Management Company, LLC serves as the investment adviser to the Fund. Advisors' Opinion:- [By pamatlarge]
Investors looking to short a particular sector can choose from several Global X long ETFs. The Global X China Consumer ETF (CHIQ) concentrates its investments in consumer cyclical goods and consumer defense goods. The Global X China Energy ETF (CHIE) primarily holds stocks in coal, oil and utility companies. The Global X China Financials ETF (CHIX) only invests in financial services companies and real estate companies. The Global X China Industrials ETF (CHII) holds stocks in industrial companies and basic materials companies. The Global X China Materials ETF (CHIM) invests in basic materials stocks. The Global X China Technology ETF (CHIB) holds technology stocks as the core of its investments. All of these ETFs are particularly sensitive to sector downturns and general economic contractions.
No comments:
Post a Comment